Latest News and Press Releases

CAMBRDIGE, U.K., Sept. 20, 2004 (PRIMEZONE) -- CeNeS Announces Positive Preliminary Results with M6G from Phase III Trial in Post-operative Pain Cambridge, UK, 20 September 2004 - CeNeS...

CAMBRIDGE, U.K., Sept. 20, 2004 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (AIM:CEN) ("CeNeS" or "the Company") today announced its unaudited interim financial results for the six months ended 30 June...

CAMBRIDGE, United Kingdom, April 20, 2004 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) ("CeNeS" or "the Company") today announced its preliminary results for the year ended 31 December...

CAMBRIDGE, United Kingdom, Sept. 30, 2003 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) (Other OTC:CPHAF) today announced its unaudited interim financial results for the six months ended 30 June...

CAMBRIDGE, United Kingdom, Sept. 01, 2003 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) (Other OTC:CPHAF) today announced that additional data will be presented in the next two months on the...

CAMBRIDGE, U.K., Aug. 8, 2003 (PRIMEZONE) -- CeNeS Pharmaceuticals plc ("CeNeS" or "the Company") (LSE:CEN) (Other OTC:CPHAF) is pleased to announce that, subject to the satisfaction of certain...

CAMBRIDGE, United Kingdom, July 2, 2003 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) today announced that it has finalised its plans for the Phase III trials of M6G (morphine-6-glucuronide) for...

CAMBRIDGE, United Kingdom, July 2, 2003 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) today announced that the board has resolved to apply for the Company's shares to be admitted to AIM...

CAMBRIDGE, United Kingdom, June 18, 2003 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) today announced that it has reached agreement with Elan Corporation plc (NYSE:ELN) to terminate the...

CAMBRIDGE, United Kingdom, May 22, 2003 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) (Other OTC:CPHAF) today announced that it has completed the sale of three of its pharmaceutical products for...